TICKERNERD
Menu
HOWLHOWLHealthcare · Biotechnology

HOWL Stock Forecast: Werewolf Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.98
−0.68% on the day

The 1 Wall Street analysts covering Werewolf Therapeutics, Inc. hold a median 12-month price target of $7 — +612.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 11 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$47.7M
Ticker Nerd rank
80 / 100
Median analyst target
$7.00
Analysts covering
1
Revenue$21.0M
Operating income$7.2M
Net income$3.7M
Free cash flow$6.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.1%
1M
+155.8%
YTD
+54.9%
1Y
−31.3%
From 52W high
−55.1%
From 52W low
+218.9%
$0.31
$2.19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HOWL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Werewolf Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
82
Accruals
79
Issuance
78
Value
72
Quality
52
Revisions
47
Volatility
42
Momentum
30

Growth (86): Sales and profits are climbing, and climbing faster than before.

Momentum (30): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HOWL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HOWL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26HOWLHigh $10.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $7.00High $10.00

The green dot is the last close — the median target sits +612.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Dec 2025HC Wainwright & Co.MaintainsBuy$10 → $4.00
18 Nov 2025B of A SecuritiesMaintainsBuy—
25 Aug 2025B of A SecuritiesMaintainsBuy—
21 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
9 May 2025WedbushMaintainsOutperform—
12 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025WedbushReiteratesOutperform—
14 Jan 2025JMP SecuritiesMaintainsMarket Outperform—
19 Nov 2024HC Wainwright & Co.ReiteratesBuy—
2 July 2024HC Wainwright & Co.ReiteratesBuy—
26 June 2024HC Wainwright & Co.ReiteratesBuy—
26 June 2024JMP SecuritiesReiteratesMarket Outperform—
4 June 2024JMP SecuritiesReiteratesMarket Outperform—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
24 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024JMP SecuritiesReiteratesMarket Outperform—
3 Apr 2024JMP SecuritiesInitiatesMarket Outperform—
7 Mar 2024HC Wainwright & Co.MaintainsBuy—
15 Nov 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HOWL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HOWL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Werewolf Therapeutics, Inc. returned −31.3% against +17.5% for the S&P 500, dividends included.

HOWL vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Oct 25Jan 26Apr 26Jul 26HOWLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HOWL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Werewolf Therapeutics, Inc. (HOWL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
2.3×

Cheaper than 49% of US stocks

Price / book
2.9×

Cheaper than 33% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
40.7%

Higher than 92% of US stocks

Net margin
−164.8%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−119.9%

Higher than 11% of US stocks

Return on assets
−27.4%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Werewolf Therapeutics, Inc. (HOWL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Werewolf Therapeutics, Inc. has a market value of $47.7M and an enterprise value of $25.7M.

  • Revenue in the twelve months to 30 June 2026: $21.0M.

  • Net income over the same four quarters: −$34.6M, a −164.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.76.

  • Free cash flow in the twelve months to 30 June 2026: −$30.1M.

  • Shares outstanding: 48.6M.

  • Trailing P/E: −0.7×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Werewolf Therapeutics, Inc. employs 39 people — $538K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

HOWL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HOWLWerewolf Therapeutics, Inc.$47.7M
80
ANVSAnnovis Bio, Inc.$47.6M
25
MCRBSeres Therapeutics, Inc.$48.0M
49
TVGNTevogen, Inc.$47.2M
15
IBOImpact BioMedical, Inc.$48.1M
23
TILInstil Bio, Inc.$50.1M
36
ATNMActinium Pharmaceuticals, Inc.$43.9M
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Werewolf Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HOWL news & analysis

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

GlobeNewsWire · 9 Sept 2026negative

Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations involving several companies, including Werewolf Therapeutics, Inc. (HOWL). The firm invites shareholders to discuss the matter at no cost.

Why it matters — The investigation announcement signals potential legal or governance scrutiny involving Werewolf Therapeutics that shareholders may want to monitor.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ)

GlobeNewsWire · 24 Aug 2026negative

Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations involving Werewolf Therapeutics and several other companies. The notice invites shareholders who own shares to contact the firm at no cost to discuss the investigation.

Why it matters — A law firm's investigation notice relating to Werewolf Therapeutics could signal potential shareholder concern or legal scrutiny regarding the company, which may be relevant for HOWL investors to monitor.

HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 23 Aug 2026negative

Investor rights law firm Halper Sadeh LLC is investigating Werewolf Therapeutics' proposed merger with Ambros Therapeutics to assess whether Werewolf shareholders will receive a fair price. Under the deal, Werewolf shareholders are expected to own approximately 6.8% of the combined company, and the firm is encouraging shareholders to learn about their rights and options.

Why it matters — A HOWL watcher would care because an investor rights law firm is scrutinizing the fairness of the merger terms for Werewolf shareholders ahead of the transaction's closing.

Why Werewolf Therapeutics stock exploded higher and what comes next?

Invezz · 21 Aug 2026positive

Werewolf Therapeutics shares rose sharply after the company announced a definitive all-stock merger with Ambros Therapeutics. The combined company will focus on Ambros' Phase 3 drug candidate neridronate for Complex Regional Pain Syndrome Type 1, supported by an oversubscribed $150 million private placement from institutional investors.

Why it matters — A HOWL watcher would care because the merger marks a major strategic pivot for the company toward a late-stage pain treatment candidate backed by significant institutional funding.

One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story

Benzinga · 21 Aug 2026positive

Werewolf Therapeutics was among the biggest pre-market movers on Friday after announcing a merger with Ambros Therapeutics, a development that a stock-research report described as a $500 million merger story and one of Israel Englander's biotech picks.

Why it matters — HOWL watchers would care because the announced merger with Ambros Therapeutics marks a significant corporate event that drove notable pre-market trading activity in the stock.

FAQ

Frequently asked questions about HOWL stock

What is the HOWL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Werewolf Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HOWL stock a buy right now?

Of the 1 analysts covering Werewolf Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Werewolf Therapeutics, Inc. 80 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HOWL?

As at 11 Sept 2026, Werewolf Therapeutics, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will HOWL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +612.6% from the last close, and Ticker Nerd's factor model ranks Werewolf Therapeutics, Inc. 80 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HOWL stock forecast for 2030?

No analyst covering Werewolf Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HOWL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has HOWL stock performed over the past year?

Werewolf Therapeutics, Inc. returned -31.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Werewolf Therapeutics, Inc. do?

Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions.

What is the latest news on HOWL?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)". Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations involving several companies, including Werewolf Therapeutics, Inc. (HOWL). The firm invites shareholders to discuss the matter at no cost.

Company

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions. The company’s current work centers on its proprietary PREDATOR platform, which is used to create INDUKINE and INDUCER molecules intended to activate selectively in diseased tissue while limiting activity in healthy tissue. Its pipeline includes immune-modulating candidates aimed at solid tumors and specific cancer targets, reflecting a concentration on oncology and immunotherapy. Werewolf Therapeutics Inc. operates as a clinical-stage developer of advanced biologic therapies, with research and development activities spanning tumor-directed immune activation and targeted protein engineering. Headquartered in Watertown, Massachusetts, the company is positioned within the biotechnology sector as a specialist in next-generation cancer therapeutics.

CEO Dr. Daniel J. Hicklin Ph.D. · 39 employees · United States · https://werewolftx.com